Last reviewed · How we verify

NCT05623644

Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy

Status unknown Last updated 21 November 2022
What this trial tests

trial in Movement Disorders in 200 participants. Status unknown.

Timeline
30 September 2022
Primary endpoint
30 November 2023
30 November 2024

Quick facts

Lead sponsorChinese PLA General Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date30 September 2022
Primary completion30 November 2023
Estimated completion30 November 2024
Sites1 location across China

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Eligibility, any sex, with Movement Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The technological advance of magnetic resonance-guided focused ultrasound (MRgFUS) has once again brought lesion therapy back to the clinical frontline for the treatment of movement disorder. Thus far, the safety of MRgFUS has been widely proven and has just been made available in China in late 2020. We attempted to analyze the neuroplasticity characteristics and altered neural circuit activity in patients subjected with MRgFUS thalamotomy via Multiple MR Imaging study, and to explore potential biomarkers that could be used to predict the treatment outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Movement Disorders

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05623644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing